Wikipedia -WSS

Wikipedia

author：Wikipedia 2025-10-01 21:10:09 - browse：733

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： FDA investigates CAR

focus

WSS

Cigna, Humana reportedly in talks to merge

Takeda, Janssen join wearable maker to measure scratching

3 questions for the future of Biden's cancer moonshot

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

CDC director unscathed in first congressional testimony

ReNAgade cuts staff seven months after raising $300 million

leisure time

Wikipedia

hotspot

How one medical school became remarkably diverse

As biotech industry slumps, bioscience job market is upside down

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Takeda, Janssen join wearable maker to measure scratching

In age of alternative facts, a scholarly course on calling out crap

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Medical leaders decry Supreme Court decision on affirmative action

Senate panel eyes new effort on drug shortages

Malaria cases in Florida and Texas: Here’s what you need to know

Bristol 'take

knowledge

Chan Zuckerberg Biohub Chicago to focus on inflammation

Will the market for weight loss drugs really reach $100 billion?

Takeda, Janssen join wearable maker to measure scratching

CDC director unscathed in first congressional testimony

Was Amgen transparent enough on FDA's concern on cancer drug?

Why Charlie Gard's case is so disturbing to Americans

explore

focus

focus

focus